These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 3976757)
21. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. Brancazio LR; Murtha AP; Heine RP N Engl J Med; 2003 Sep; 349(11):1087-8; author reply 1087-8. PubMed ID: 12968095 [No Abstract] [Full Text] [Related]
22. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery. Facchinetti F; Vaccaro V Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671 [TBL] [Abstract][Full Text] [Related]
23. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going? Manuck TA Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068 [TBL] [Abstract][Full Text] [Related]
25. Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial. Facchinetti F; Vergani P; Di Tommaso M; Marozio L; Acaia B; Vicini R; Pignatti L; Locatelli A; Spitaleri M; Benedetto C; Zaina B; DʼAmico R Obstet Gynecol; 2017 Jul; 130(1):64-70. PubMed ID: 28594783 [TBL] [Abstract][Full Text] [Related]
26. The use of 17-hydroxy progesterone in women with arrested preterm labor: a randomized clinical trial. Briery CM; Klauser CK; Martin RW; Magann EF; Chauhan SP; Morrison JC J Matern Fetal Neonatal Med; 2014 Dec; 27(18):1892-6. PubMed ID: 24512252 [TBL] [Abstract][Full Text] [Related]
27. Prophylactic use of hydroxyprogesterone caproate in abdominal surgery during pregnancy. A retrospective evaluation. Hill LM; Johnson CE; Lee RA Obstet Gynecol; 1975 Sep; 46(3):287-90. PubMed ID: 1161231 [TBL] [Abstract][Full Text] [Related]
28. ACOG Committee Opinion. Use of progesterone to reduce preterm birth. American College of Obstetricians and Gynecologists Obstet Gynecol; 2003 Nov; 102(5 Pt 1):1115-6. PubMed ID: 14672496 [TBL] [Abstract][Full Text] [Related]
35. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. Lim AC; Bloemenkamp KW; Boer K; Duvekot JJ; Erwich JJ; Hasaart TH; Hummel P; Mol BW; Offermans JP; van Oirschot CM; Santema JG; Scheepers HC; Schöls WA; Vandenbussche FP; Wouters MG; Bruinse HW; BMC Pregnancy Childbirth; 2007 Jun; 7():7. PubMed ID: 17578562 [TBL] [Abstract][Full Text] [Related]
36. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter? How HY; Barton JR; Istwan NB; Rhea DJ; Stanziano GJ Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411 [TBL] [Abstract][Full Text] [Related]
37. [Progesterone and 6-methyl-17-hydroxyprogesterone acetate in the treatment of threatened premature labor]. CIULLA U Ann Ostet Ginecol; 1960 May; 82():537-45. PubMed ID: 13810388 [No Abstract] [Full Text] [Related]
38. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety. O'Brien JM; Lewis DF Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340 [TBL] [Abstract][Full Text] [Related]
39. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening. Kumar D; Moore RM; Mercer BM; Mansour JM; Mesiano S; Schatz F; Lockwood CJ; Moore JJ Am J Obstet Gynecol; 2017 Dec; 217(6):695.e1-695.e14. PubMed ID: 29031893 [TBL] [Abstract][Full Text] [Related]
40. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage. Rebarber A; Cleary-Goldman J; Istwan NB; Rhea DJ; Desch C; Russo-Stieglitz K; Saltzman DH Am J Perinatol; 2008 May; 25(5):271-5. PubMed ID: 18401840 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]